1. COVID-19 threatens M&A already in process— Physician survey shows widespread concern about access to testing and medical supplies for COVID— Novartis cancels $1B generics sale — See more on our front page news Stay updated with the latest pharma-related coronavirus news on our new page
    Dismiss Notice
  2. Think you have witnessed fraud?Ask a Whistleblower Attorney -- a chance to discuss whistleblower-related legal issues with practicing whistleblower attorneys.
    Dismiss Notice

When will they be held responsible?

Discussion in 'GlaxoSmithKline Lab Personnel' started by Anonymous, Feb 26, 2015 at 9:30 PM.

Tags: Add Tags
  1. Anonymous

    Anonymous Guest


  2. Anonymous

    Anonymous Guest

    Sir Andrew had his total compensation cut by ~45% this year. From 7.2 million pounds to 3.9 million pounds.
     
  3. Anonymous

    Anonymous Guest

    OMG!!! However will he survive on such a paltry sum?
     
  4. Anonymous

    Anonymous Guest

    Considering the company performance, his bonus should have been no more than 1 pound, with a cut in salary.
     
  5. Anonymous

    Anonymous Guest

    Now that we've eliminated the key talent in RTP that was clogging the decisions and the system it already seems like there has been an improvement in operational efficiency.

    I'd say we're on the right track but might have to come back to chop off a couple more legacy folks.
     
  6. Anonymous

    Anonymous Guest

    So, why is it that GSK make such awful deals. Here is an example of one just announced that would have fit nicely into the GSK portfolio, and would make money too.
    http://www.bloomberg.com/news/artic...rket-achillion-s-hepatitis-c-drugs?cmpid=yhoo

    Why can't GSK management think and act in GSK's purpseful interest to make and sell new and innobative drug as the driver and priority, instead of being interested in themselves, always having to be right, and not consider good science?
     
  7. anonymous

    anonymous Guest

  8. anonymous

    anonymous Guest

  9. anonymous

    anonymous Guest

  10. anonymous

    anonymous Guest

    Well folks, the chance to make a big statement about improving Pharma R&D with the choice for a Witty replacement is more and more of business as usual.
    http://finance.yahoo.com/news/big-p...yYjJiBGNvbG8DYmYxBHBvcwMyBHZ0aWQDBHNlYwNzYw--
    Also a continuation for personal objectives to drive some of the most important corporate decisions: "Glaxo Chairman Philip Hampton is spearheading a government-backed review on how to increase the number of female executives at the U.K.’s biggest 350 companies."